REFERENCES
1. Kaprin A.D. Malignant neoplasms in Russia in 2020 (morbidity and mortality). In: A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2021: 252 p. (in Russian)
2. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. World Health Organization, 2021.
3. Cervical intraepithelial neoplasia, erosion and ectropion of the cervix: Clinical guidelines, Rossiyskoe obshhestvo akusherov-ginekologov, 2020. (in Russian)
4. Bayramova G.R., Prilepskaya V.N., Smol’nikova V.Yu., Yureneva S.V. HPV-associated cervicitis: diagnosis, treatment and prevention. A textbook. Moscow: ID Tret’yakov, 2022: 90 p. (in Russian)
5. Inturrisi F., Bogaards J.A., Heideman D.A.M., Meijer C.J.L.M., Berkhof J. Risk of cervical intraepithelial neoplasia grade 3 or worse in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison. Cancer Epidemiol Biomarkers Prev. 2021; 30 (3): 485–91. DOI: https://doi.org/10.1158/1055-9965
6. Bonde J., Floore A., Ejegod D., Vink F.J., Hesselink A., van de Ven P.M., et al. Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: a large European multicenter study. Int J Cancer. 2021; 148 (2): 396–405. DOI: https://doi.org/10.1002/ijc.33320 Epub 2020 Oct 21. PMID: 32997803; PMCID: PMC7756277.
7. Hampl M., Hesselink A.T., Meijer C.J.L.M., Denecke A., Einhorn I., Reinecke-Luethge A., et al.; Members of the German Study Group of Colposcopy (SGK). Evaluation of FAM19A4/miR124-2 methylation performance in the management of CIN3 diagnosed pregnant women. Int J Cancer. 2022; 151 (9): 1578–85. DOI: https://doi.org/10.1002/ijc.34153 Epub 2022 Jun 20. PMID: 35666529.
8. Hillyar C.R., Kanabar S.S., Pufal K.R., Lawson A.W., Saw Hee J.L., Rallis K.S., et al. A systematic review and meta-analysis of the diagnostic effectiveness of human papillomavirus methylation biomarkers for detection of cervical cancer. Epigenomics. 2022; 14 (18): 1055–72. DOI: https://doi.org/10.2217/epi-2022-0160 Epub 2022 Sep 28. PMID: 36169190.
9. Zhang L., Tan W., Yang H., Zhang S., Dai Y. Detection of host cell Gene/HPV DNA methylation markers: a promising triage approach for cervical cancer. Front Oncol. 2022; 12: 831949. DOI: https://doi.org/10.3389/fonc.2022.831949 PMID: 35402283; PMCID: PMC8990922.
10. Kremer W.W., Steenbergen R., Heideman D., Kenter G.G., Meijer C. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG. 2021; 128 (3): 504–14. DOI: https://doi.org/10.1111/1471-0528.16395 Epub 2020 Aug 9. PMID: 32619334; PMCID: PMC7818489.
11. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3 (6): 415–28. DOI: https://doi.org/10.1038/nrg816 PMID: 12042769.
12. Herman J.G., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA. 1998; 95: 6870–5.
13. El Aliani A., El-Abid H., El Mallali Y., Attaleb M., Ennaji M.M., El Mzibri M. Association between gene promoter methylation and cervical cancer development: global distribution and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2021; 30 (3): 450–9. DOI: https://doi.org/10.1158/1055-9965.epi-20-0833 Epub 2021 Jan 13. PMID: 33441308.
14. Pfeifer G.P., Tang M., Denissenko M.F. Mutation hotspots and DNA methylation. Curr Top Microbiol Immunol. 2000; 249: 1–19.
15. Yoon J.H., et al. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers. Cancer Res. 2001; 61: 7110–7.
16. Kong L., Wang L., Wang Z., Xiao X., You Y., Wu H., et al. DNA methylation for cervical cancer screening: a training set in China. Clin Epigenetics. 2020; 12 (1): 91. DOI: https://doi.org/10.1186/s13148-020-00885-7 PMID: 32576279; PMCID: PMC7310541.
17. Vink F.J., Meijer C.J.L.M., Clifford G.M., Poljak M., Oštrbenk A., Petry K.U., et al. FAM19A4/miR124-2 methylation in invasive cervical cancer: a retrospective cross-sectional worldwide study. Int J Cancer. 2020; 147 (4): 1215–21. DOI: https://doi.org/10.1002/ijc.32614 Epub 2019 Sep 9. PMID: 31390052; PMCID: PMC7383900.
18. De Strooper L.M.A., Berkhof J., Steenbergen R.D.M., Lissenberg-Witte B.I., Snijders P.J.F., Meijer C., et al. Cervical cancer risk in HPV-positive women after a negative FAM19A4/mir124-2 methylation test: a post hoc analysis in the POBASCAM trial with 14 year follow-up. Int J Cancer. 2018; 143: 1541–8.
19. Bu Q., Wang S., Ma J., Zhou X., Hu G., Deng H., et al. The clinical significance of FAM19A4 methylation in high-risk HPV-positive cervical samples for the detection of cervical (pre)cancer in Chinese women. BMC Cancer. 2018; 18 (1): 1182. DOI: https://doi.org/10.1186/s12885-018-4877-5 PMID: 30486875; PMCID: PMC6263049.
20. Wang S.F., Bu Q.W., Zhang L., Ma J.W., Heng Y., Luo J.Q., et al. [Detection and analysis of FAM19A4 promoter methylation in cervical exfoliated cells]. Zhonghua Yi Xue Za Zhi. 2019; 99 (25): 1963–7. DOI: https://doi.org/10.3760/cma.j.issn.0376-2491.2019.25.012 PMID: 31269601. (in Chinese)
21. Wang F., Liu M., Li X., Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 2013; 587 (5): 488–95. DOI: https://doi.org/10.1016/j.febslet.2013.01.016 Epub 2013 Jan 18. PMID: 23337879.
22. Henken F.E., Wilting S.M., Overmeer R.M., van Rietschoten J.G., Nygren A.O., Errami A., et al. Sequential gene promoter methylation during HPV-induced cervical carcinogenesis. Br J Cancer. 2007; 97: 1457–64. DOI: https://doi.org/10.1038/sj.bjc.6604055
23. Widschwendter A., Muller H.M., Fiegl H., Ivarsson L., Wiedemair A., Muller-Holzner E., et al. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res. 2004; 10: 565–71. DOI: https://doi.org/10.1158/1078-0432.CCR-0825-03
24. Overmeer R.M., Henken F.E., Bierkens M., Wilting S.M., Timmerman I., Meijer C.J., et al. Repression of MAL tumor suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol. 2009; 219 (3): 327–36.
25. Lujambio A., Ropero S., Ballestar E., Fraga M.F., Cerrato C., Setien F., et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res. 2007; 67: 1424–9. DOI: https://doi.org/10.1158/0008-5472.CAN-06-4218
26. Wilting S.M., van Boerdonk R.A., Henken F.E., Meijer C.J., Diosdado B., Meijer G.A., et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer. 2010; 9: 167. DOI: https://doi.org/10.1186/1476-4598-9-167 PMID: 20579385; PMCID: PMC2917428.
27. Shen S., Zhang S., Liu P., Wang J., Du H. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet. 2020; 248–249: 25–30. DOI: https://doi.org/10.1016/j.cancergen.2020.09.003